

**Target Journal:** Chest

**TITLE PAGE**

**Title:**

**Remote exposure to secondhand tobacco smoke is associated with lower exercise capacity through effects on oxygen pulse- a proxy of cardiac stroke volume**

**Running title:** Cardiovascular health effects of secondhand smoke

**Author list:**

Siyang Zeng, MS <sup>1,2</sup>, Michelle Dunn, BS, BA <sup>2,3</sup>, Warren M Gold, MD <sup>3</sup>, Mehrdad Arjomandi MD <sup>2,3,4</sup>

**Affiliation:**

<sup>1</sup> Department of Biomedical Informatics and Medical Education, University of Washington, Seattle, WA, USA

<sup>2</sup> San Francisco Veterans Affairs Medical Center; San Francisco; California, USA

<sup>3</sup> Division of Pulmonary, Critical Care, Allergy and Immunology, and Sleep Medicine, Department of Medicine, University of California, San Francisco, California, USA

<sup>4</sup> Division of Occupational and Environmental Medicine; Department of Medicine, University of California, San Francisco, California, USA

**Corresponding authors information:**

**Mehrdad Arjomandi, MD**

Department of Medicine

University of California, San Francisco

San Francisco Veterans Affairs Medical Center

Building 203, Room 3A-128, Mailstop 111-D

4150 Clement Street, San Francisco, CA 94121

TEL (415) 221-4810 x24393

EMAIL [mehrdad.arjomandi@ucsf.edu](mailto:mehrdad.arjomandi@ucsf.edu)

**Authors' Contributions**

Conceived and designed the current manuscript study: MA

Developed study protocols: WMG, MA

Collected samples and data: SZ, MD, JB, WMG, MA

Analyzed and interpreted data: SZ, MD, JB, JK, MA

Prepared and edited the manuscript: SZ, MD, JB, WMG, MA

Obtained funding: MA

**Summary conflict of interest:**

Authors report no conflict of interest related to this work

**Footnote:**

This work was supported by:

1. Flight Attendant Medical Research Institute (FAMRI) (012500WG and CIA190001 to MA).
2. California Tobacco-Related Disease Research Program (TRDRP) (T29IR0715 to MA).
3. The Department of Veterans Affairs (CXV-00125 to MA).
4. National Library of Medicine Training Grant (NIH: T15LM007442 to SZ)

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The statements and conclusions in this publication are those of the authors and not necessarily those of the funding agency. The mention of commercial products, their source, or their use in connection with the material reported herein is not to be construed as an actual or implied endorsement of such products.

**Notation of prior abstract publication/presentation:**

Some of the results of this study have been previously reported in the form of an abstract (American Thoracic Society International Meeting 2020: Am J Respir Crit Care Med 2020;201:A7591)

**Acknowledgement:**

The authors would like to thank Wendy Ching, BS, Charlotte Hunt, BS, and Warren M Gold, MD, for their assistance with performing the cardiopulmonary exercise testing.

**Abbreviation list:**

**COPD:** Chronic obstructive pulmonary disease

**CT:** Computerized tomography

**DM:** Density mask

**EELV:** End-expiratory lung volume

**EFL:** Expiratory flow limitation

**FAMRI:** Flight Attendant Medical Research Institute

**FEF<sub>25-75</sub>:** Forced expiratory flow at 25% to 75% of FVC

**FEF<sub>75</sub>:** Forced expiratory flow at 75% of FVC

**FEV<sub>1</sub>:** Forced expiratory volume in 1 second

**FVC:** Forced vital capacity

**GLI:** Global Lung Function Initiative

**GOLD:** Global Initiative on Obstructive Lung Disease

**HU:** Hounsfield unit

**IC:** Inspiratory capacity

**LLN:** Lower limit of normal

**MEF:** Maximum expiratory flow

**PFT:** Pulmonary function test

**RV:** Residual volume

**SHS:** Secondhand tobacco smoke

**TLC:** Total lung capacity

**V<sub>E</sub>:** Minute ventilation

**V<sub>FL</sub>:** Volume of the tidal breath that is flow-limited on expiration

**V<sub>O<sub>2</sub>Max</sub>:** Maximum oxygen uptake

**V<sub>T</sub>:** Tidal volume

**Watts<sub>Max</sub>:** Maximum work achieved in watts

## ABSTRACT

**Background:** Prolonged past exposure to secondhand tobacco smoke (SHS) is associated with exercise limitation. Pulmonary factors including air trapping contribute to this limitation but the contribution of cardiovascular factors is unclear.

**Methods:** To determine contribution of cardiovascular mechanisms to SHS-associated exercise limitation, we examined the cardiovascular responses to maximum effort exercise testing in 166 never-smokers with remote but prolonged occupational exposure to SHS and no known history of cardiovascular disease except nine with medically-controlled hypertension. We estimated the contribution of oxygen-pulse (proxy for cardiac stroke volume) and changes in systolic (SBP) and diastolic blood pressures (DBP) and heart rate (HR) over workload towards exercise capacity, and examined whether the association of SHS with exercise capacity was mediated through these variables.

**Results:** Oxygen consumption ( $VO_{2Peak}$ ) and oxygen-pulse ( $O_2\text{-Pulse}_{Peak}$ ) at peak exercise were  $1,516 \pm 43$  mL/min ( $100 \pm 23$  %predicted) and  $10.6 \pm 2.8$  mL/beat ( $117 \pm 25$  %predicted), respectively, with 91 (55%) and 43 (26%) of subjects not being able to achieve their maximum predicted values. Sixty-two percent showed hypertensive response to exercise by at least one established criterion. In adjusted models,  $VO_{2Peak}$  was associated directly with  $O_2\text{-Pulse}$  and inversely with rise of SBP and DBP over workload (all  $P < 0.05$ ). Moreover, SHS exposure association with  $VO_{2Peak}$  was mainly (84%) mediated through its effect on oxygen-pulse ( $P = 0.034$ ). Notably, although not statistically significant, a large proportion (60%) of air trapping effect on  $VO_{2Peak}$  seemed to be mediated through oxygen-pulse ( $P = 0.066$ ).

**Discussion:** In a never-smoker population with remote prolonged exposure to SHS, abnormal escalation of afterload and an SHS-associated reduction in cardiac output contributed to lower exercise capacity.

## Introduction

Secondhand tobacco smoke (SHS) remains a major public health problem.<sup>1,2</sup> Although SHS exposure among nonsmokers in the United States has declined from 88% in 1988 to 25% in 2014, the rate of decline has plateaued with one in four nonsmokers, including 14 million children, continue to be exposed to SHS annually between 2011 and 2014.<sup>3</sup> This substantial continued exposure is important particularly as the generations that endured the highest amount of SHS exposure are aging, a process which could accentuate the SHS-related health problems that may have been previously too subtle to be recognized.

Although immediate health effects of exposure to SHS have been studied,<sup>4-9</sup> its long-term consequences, particularly the effect of remote exposures, have been more difficult to examine in part due to challenges with exposure assessment. Never-smoking flight crew who worked on commercial aircrafts before the enactment of the smoking ban were exposed to heavy SHS in aircraft cabin for many years, in a range similar to the nicotine exposure burden experienced by "light" smokers.<sup>10,11</sup> The regularity of this intense exposure in the cabin work environment lends itself to relatively accurate SHS exposure quantification through employment history,<sup>12</sup> and makes the exposed flight crew a unique population in which the long-term health effects of previous exposure to SHS could be examined as a form of "natural" experiment that is also generalizable to other SHS-exposed populations.

In previous studies of never-smoking flight crew with history of remote but prolonged exposure to SHS in aircraft cabin, we examined the pulmonary health effects of long-term exposure to SHS and showed the association of those outcomes with the number of years during which the flight crew were exposed to SHS in aircraft cabin.<sup>13-15</sup> While this never-smoking SHS-exposed cohort had no evidence of spirometric chronic obstructive pulmonary disease (COPD) (a

preserved ratio of forced expiratory volume in 1 second to forced vital capacity [FEV<sub>1</sub>/FVC]), they had abnormal lung function that were suggestive of presence of an occult early/mild obstructive lung disease.<sup>15</sup> In the current study, we wished to examine the cardiovascular health effects of remote but prolonged exposure to SHS in this never-smoking cohort with evidence of early obstructive lung disease. We hypothesized that prolonged exposure to SHS contributes to exercise limitation through its adverse cardiovascular health effects, in addition to its contribution through pulmonary mechanisms (air trapping). To evaluate this hypothesis, we analyzed the cohort's cardiovascular response to maximum effort cardiopulmonary exercise testing.

## **Methods**

### Study Overview

This was a *post-hoc* analysis of data collected as part of the Secondhand Smoke Respiratory Health Study, an observational cohort study of nonsmoking subjects with a range of occupational SHS exposure, as previously described.<sup>13-15</sup> Briefly, between July 2007 and July 2015, we recruited US airline flight crewmembers with a history of occupational exposure to SHS, along with nonsmoker controls without such occupational exposure, who were participating in a larger study of cardiopulmonary health effects of prolonged remote exposure to SHS.<sup>15</sup> The participants were characterized by respiratory symptom questionnaires, full pulmonary function testing (PFT), and a maximum effort cardiopulmonary exercise testing (CPET). We used the data from this cohort to perform a *post-hoc* analysis to determine the associations among exercise capacity (volume of oxygen uptake at peak exercise [VO<sub>2Peak</sub>]), cardiovascular responses to maximum effort CPET (oxygen-pulse [O<sub>2</sub>-Pulse; a proxy for cardiac stroke volume], systolic and diastolic blood pressure

[SBP and DBP], and heart rate [HR]), years of airline employment during which the subjects worked in smoky cabin (cabin SHS exposure), and their interactions with each other as well as with air trapping (RV/TLC), which we had previously shown to be associated with  $VO_{2Peak}$ .

### Study Population

The Secondhand Smoke Respiratory Health Study recruited the US airline flight crewmembers as part of an investigation of the potential adverse health effects of the cabin environment on those employed before and after introduction of the ban on smoking in U.S. commercial aircraft. Crewmembers were eligible to participate in the study if they had worked  $\geq 5$  years in aircraft. A referent group of “sea-level” subjects who lived in San Francisco Bay area and had never been employed as airline crewmembers were also recruited. All subjects were nonsmokers defined by never-smoking or, in ever smokers, no smoking for  $\geq 20$  years and a cumulative history of smoking  $< 20$  pack-years. Subjects with known history of pulmonary (such as asthma or COPD) or cardiovascular disease (such as coronary artery disease or heart failure) were excluded. Subjects with known history of hypertension were included if their blood pressure was medically controlled as defined by  $SBP \leq 150$  and  $DBP \leq 90$  at the time of visit. Overall, out of the 179 subjects who underwent cardiopulmonary exercise testing (CPET), 166 subjects were included in this analysis.<sup>15</sup>

The UCSF Institutional Review Board (IRB) and the San Francisco VA Medical Center Committee on Research and Development approved study protocols. Written IRB-approved informed consent and Health Insurance Portability and Accountability Act (HIPAA) were obtained from all study participants. Subjects received monetary compensation for their participation in the study.

### SHS Exposure Characterization

SHS exposure was characterized by a questionnaire developed by the UCSF Flight Attendant Medical Research Institute (FAMRI) Center of Excellence,<sup>16</sup> and modified to acquire information on airline-related occupational history, as described previously.<sup>13,14</sup> Briefly, this included employer airlines, duration of employment, and flight routes with quantification of “cabin SHS exposure” as the number of years during which the crewmembers were exposed to SHS in aircraft. Other possible sources of SHS exposure were also explored by questioning subjects about their non-cabin exposures in additional settings, as described previously.<sup>17</sup>

### Pulmonary Function Testing

Pulmonary function studies were conducted according to the American Thoracic Society (ATS) and European Respiratory Society (ERS) guidelines<sup>18-23</sup>. Routine pulmonary function tests were performed in the seated position using a model Vmax 229 CareFusion (CareFusion Corp., Yorba Linda, CA) and nSpire body plethysmograph (nSpire Health Inc., Longmont, CO) as described previously.<sup>13</sup> This included measurement spirometry including flows low lung volumes<sup>24</sup>; lung volume by single breath dilution<sup>25,26</sup> and plethysmography<sup>27</sup>; airway resistance during panting at functional residual capacity (FRC)<sup>28,29</sup>; and single breath carbon monoxide diffusing capacity.<sup>30</sup> Bronchodilator responsiveness was not performed. Hyperinflation and air trapping, which is inferred from an increase in FRC or residual volume (RV), was quantified using FRC or RV to total lung capacity (TLC) ratio (FRC/TLC or RV/TLC).

### Cardiopulmonary Exercise Testing

Subjects performed physician-supervised, symptom-limited, progressively increasing exercise tests in the supine position on an electromagnetically braked, supine cycle ergometer (Medical Positioning Inc. Kansas City, MO). The protocol consisted of 3-min rest, 1-min unloaded (freewheeling) cycling at 60 to 65 revolution per minute (rpm), followed by increasing

work rate of 20 to 40 Watts at 2-minute intervals (stages) to a maximum tolerated, and 5-min of recovery. Subjects were encouraged to give their best effort, and during testing, were encouraged to continue exercise until a  $\text{VO}_2$  plateau effect on a breath-to-breath analysis of oxygen consumption was visually observed; however, they were advised that they could stop voluntarily at any time they believed they could not continue.

Twelve-lead electrocardiogram (ECG), heart rate (HR), and oxyhemoglobin saturation by pulse oximetry ( $\text{O}_2\text{sat}$ ) were monitored continuously, and blood pressure (BP) (measured manually by a physician with a cuff) was recorded every 2 min during the second minute of each stage. Minute ventilation ( $V_E$ ), oxygen uptake ( $\text{VO}_2$ ), and carbon dioxide output ( $\text{VCO}_2$ ) were measured breath-by-breath with an open-circuit metabolic cart (model Vmax 229, CareFusion, Yorba Linda, CA). Immediately before all tests, the gas analyzers were calibrated using reference gases of known concentrations and the ventilometer was calibrated using a 3-liter syringe (Hans Rudolph, Kansas, MO). The metabolic system was verified using four trained technicians who provided monthly exercise values as biological standards for the Laboratory.

Peak exercise gas exchange variables ( $\text{VO}_2$ ,  $\text{VCO}_2$ , and  $V_E$ ) were estimated as the last 30-second average value obtained during the highest stage of the exercise test that subject was able to complete, as defined by continuous cycling at the required 60 to 65 rpm during that stage for greater than 1 minute. The volumes of the flow meter, mouthpiece, and filter (70 mL x breathing frequency) were subtracted from  $V_E$  for the  $V_E/\text{VCO}_2$  calculations. Anaerobic threshold (AT) was determined by the V-slope method.<sup>31,32</sup>

The subject's perception of level of effort and exertion, breathlessness, and fatigue was documented during the second minute of every stage using the modified Borg Rating of Perceived Exertion (Borg), the Category-Ratio Scale anchored at number 10 (CR10).<sup>33</sup>

## Respiratory Symptom Scoring

Respiratory symptoms were assessed using modified Medical Research Council (mMRC) Dyspnea Scale<sup>34</sup> and another self-reported questionnaire (UCSF FAMRI Center of Excellence questionnaire<sup>16</sup>) that elicited symptoms of dyspnea, cough, and subjects' perception of a decreased level of exertion compared to peers over the year preceding enrollment. A dichotomous indicator of respiratory symptoms was defined by mMRC  $\geq 1$  or report of at least one respiratory symptom on the FAMRI questionnaire.

## Data Analysis

Percent predicted as well as lower and upper limits of normal (LLN and ULN) values for measures of Spirometry and lung volumes at rest and cardiopulmonary responses to exercise were calculated using Global Lung Function Initiative (GLI), Quanjer et al., and Wasserman predicted formulas, respectively.<sup>35-37</sup>

Distributions of subject characteristics, pulmonary function, cardiopulmonary exercise, and SHS exposure quantification variables were examined. Changes in HR, SBP, DBP, and O<sub>2</sub>-Pulse with respect to the workload were approximated by estimating the slopes from linear regression modeling of the measures over workload at each stage. Peak cardiopulmonary exercise variables were estimated using the last 30-second average values obtained during the highest stage of the exercise test as described above.

Associations between exercise capacity (VO<sub>2Peak</sub>) and each of the cardiovascular outputs (including SBP, DBP, and O<sub>2</sub>-Pulse) were examined in univariate linear regression models with adjustment for covariates (age, sex, height, and BMI unless noted otherwise) and the baseline value of the respected variable. Similarly, associations between presence of respiratory symptoms (mMRC) and each of the cardiovascular outputs were examined in univariate logistic

regression models with adjustment for covariates. Additionally, associations between each of the cardiovascular outputs (SBP, DBP, and O<sub>2</sub>-Pulse) and baseline air trapping (FRC/TLC or RV/TLC) as a pulmonary factor affecting exercise capacity and cardiovascular outputs,<sup>38-41</sup> and SHS exposure were examined using linear regression models.

The cardiovascular variables that were statistically significant predictor of exercise capacity (VO<sub>2Peak</sub>) (or respiratory symptoms [mMRC]) were then used in comprehensive regression models with inclusion of all relevant cardiovascular outputs, air trapping (FRC/TLC or RV/TLC), and SHS exposure as predictors to examine their association with VO<sub>2Peak</sub> and mMRC while accounting for the interrelationships among the predictors.

To assess whether associations between VO<sub>2Peak</sub> (or mMRC) and SHS exposure or air trapping (FRC/TLC or RV/TLC) were mediated through cardiovascular outputs, we performed mediation analyses with VO<sub>2Peak</sub> (or mMRC) (dependent variable), SHS exposure or air trapping (independent variable), and cardiovascular outputs (mediator variables), with inclusion of covariates using the “mediation” package in R.<sup>42</sup> To assess robust estimations, the bootstrap method with 1000 resamples from the data was applied to obtain the estimated proportion of mediation and the corresponding P-value.

For each analysis, the total number of subjects who had complete set of data for that analysis was reported along with the results from the regression modeling or mediation analysis.

## RESULTS

### Subject Characteristics

The characteristics of the 166 participants included in this analysis are shown in **Table 1**. The subjects were predominantly women (150 [90%]). All were never-smokers (<100 cigarettes

lifetime) with the exception of one who had smoked 0.7 pack-years. All subjects had exposure to SHS with 63% and 35% reporting childhood and adult home SHS exposure, respectively. Ninety (54%) had been exposed to cabin SHS during their airline employment for an average of  $16.8 \pm 8.8$  years (median [IQR] <total range> of 18 [10-24] <1-31> years). None of the subjects included in the analysis reported any history of cardiovascular or pulmonary diseases with the exception of nine who had a history of well-controlled hypertension, eight of whom on medical management (two on lisinopril, one on verapamil, one on atenolol, one on hydrochlorothiazide, one on combination hydrochlorothiazide and triamterene, one on combination hydrochlorothiazide and benazepril, and one on an unknown medication).

All subjects had preserved spirometry (normal  $FEV_1/FVC$  and  $FEV_1$  by LLN criterion) but some had mildly reduced diffusing capacity at  $79 \pm 10$  (median [IQR] <total range> of 79 [72-86] <53-101> %predicted). The subjects had FRC/TLC of  $0.53 \pm 0.08$  (at  $99 \pm 14$  %predicted; median [IQR] <total range> of 99 [91-107] <54-129> %predicted) and RV/TLC of  $0.34 \pm 0.07$  (at  $90 \pm 12$  % predicted; median [IQR] <total range> of 90 [82-97] <53-120> % predicted).

### **Pulmonary response to exercise**

Although the average volume of oxygen consumption at peak exercise ( $VO_{2Peak}$ ) was  $1,513 \pm 429$  mL/min ( $100 \pm 23$  %predicted), only 75 (45.2%) of subjects achieved their 100% predicted value (median [IQR] <total range>  $VO_{2Peak}$  of 97 [84-113] <53-186> %predicted). The pulmonary response to exercise was remarkable for a peak-exercise minute ventilation ( $V_{EPeak}$ ) of  $56.1 \pm 15.0$  L/min at  $114 \pm 26$  %predicted that was inappropriately elevated for  $VO_{2Peak}$  achieved. Despite this high  $V_{EPeak}$ , tidal volumes at peak exercise ( $V_{TPeak}$ ) only reached a high value of 85% of predicted value ( $1.68 \pm 0.41$  L; median [IQR] <total range> of 83 [75-94] <49-134> %predicted), implicating an abnormally elevated respiratory rate, although the peak-

exercise respiratory rate ( $RR_{Peak}$ ) remained  $<50$  breaths per minute threshold in 89% (148 out of 166) of the subjects and  $<60$  breaths per minute in all but 1 subject ( $35.0 \pm 9.0$  breaths/min; median [IQR]  $<total\ range>$  of  $33.0$  [ $28.8-40.0$ ]  $<15.0-69.0>$  breaths/min) (**Table 2**). Finally, anaerobic threshold ( $VO_{2AT}$ ) determined by V slope method was reached at  $65 \pm 16\%$  of maximum predicted  $VO_2$  (median [IQR]  $<total\ range>$  of  $66$  [ $53-75$ ]  $<27-106>$  %predicted) (**Table 2**).

### **Cardiovascular response to exercise**

None of the subjects reported any chest pain, chest tightness, lightheadedness, or dizziness during the CPET. None had any clinically significant electrocardiographic (ECG) changes or arrhythmia besides occasional premature ventricular contractions that did not increase in frequency with exercise testing. All subjects surpassed their anaerobic threshold. All reported ceasing exercise due to dyspnea or leg fatigue. Nevertheless, many had abnormal cardiovascular response to exercise as described below.

Although only 9 (5%) subjects had reported history of hypertension (with their hypertension well-controlled), 62% percent of the subjects (98 out of 158) showed hypertensive response to exercise by at least one established criterion (**Table 2**). Oxygen-pulse at peak exercise ( $O_2\text{-Pulse}_{Peak}$ ) was  $10.6 \pm 2.8$  mL/beat ( $117 \pm 25$  %predicted; median [IQR]  $<total\ range>$  of  $112$  [ $99-134$ ]  $<74-189>$  %predicted), with 43 (25.9%) subjects not achieving their 100% predicted values. At anaerobic threshold,  $O_2\text{-Pulse}$  was  $8.7 \pm 2.6$  mL/beat ( $73 \pm 26$  %predicted; median [IQR]  $<total\ range>$  of  $71$  [ $55-88$ ]  $<21-185>$  %predicted) (**Table 2**).

Furthermore, ventilatory efficiency ( $V_E/VCO_2$ ) at peak exercise and anaerobic threshold were  $30.9 \pm 4.1$  (median [IQR]  $<total\ range>$  of  $106$  [ $103-117$ ]  $<89-144>$  %predicted) and  $31.6 \pm 3.9$  (median [IQR]  $<total\ range>$  of  $110$  [ $105-119$ ]  $<89-157>$  %predicted), respectively.

The lowest  $V_E/V_{CO_2}$  was  $29.4 \pm 4.5$  (median [IQR] <total range> of 105 [99-110] <4-207> %predicted) (Table 2).

### **Association of $VO_{2Peak}$ with cardiovascular response measures, air trapping, and SHS exposure**

In univariate models that included each cardiopulmonary exercise testing (CPET) output separately as a predictor with adjustment for age, sex, height, BMI, and baseline value of that CPET variable,  $VO_{2Peak}$  was directly associated with  $O_2$ -Pulse and heart rate at peak exercise ( $O_2$ -Pulse<sub>Peak</sub> and HR<sub>Peak</sub>) and inversely with the rate of change in HR, SBP, and DBP over workload (HR<sub>Slope</sub>, SBP<sub>Slope</sub>, DBP<sub>Slope</sub>) (all  $P < 0.05$ ) (Table 3). Similarly,  $VO_{2Peak}$  was associated with respiratory rate, tidal volume, and minute ventilation at peak exercise (RR<sub>Peak</sub>,  $V_{TPeak}$ ,  $V_{EPeak}$ ) (all  $P < 0.05$ ) (Table 3).  $VO_{2Peak}$  was also inversely associated with measures of air trapping (FRC/TLC and RV/TLC) and with years of exposure to cabin SHS (all  $P < 0.05$ ), but was not significantly associated with non-cabin SHS exposure (Table 3).

In age, sex, height, and BMI-adjusted multivariate modeling that included all cardiovascular outputs of exercise that were significantly associated with respiratory symptoms and  $VO_{2Peak}$  in univariate modeling,  $VO_{2Peak}$  was directly associated with  $O_2$ -Pulse<sub>Peak</sub> and HR<sub>Slope</sub>, and inversely with SBP<sub>Slope</sub> (Table 4). In multivariate model that included all cardiovascular and pulmonary outputs of exercise that were significantly associated with  $VO_{2Peak}$  in univariate modeling, only  $O_2$ -Pulse<sub>Peak</sub>, HR<sub>Slope</sub>, SBP<sub>Slope</sub>, and  $V_{EPeak}$  retained their statistical significance (Table 5).

### **Association of respiratory symptoms with cardiovascular response measures**

The associations of respiratory symptoms at rest (as measured by mMRC and FAMRI questionnaires) and at peak exercise (as measured by Borg Scale) from univariate regression

modeling with each cardiopulmonary exercise testing (CPET) output after adjustment for age, sex, height, BMI, and the baseline value of each CPET variable examined are shown in **Table 6**. Overall, respiratory symptoms showed significant associations with only a few CPET output including  $O_2$ -Pulse, HR, and  $V_E$  at peak exercise and RV/TLC at baseline. Higher  $O_2$ -Pulse<sub>Peak</sub> was associated with lower respiratory symptoms at baseline and at peak exercise. On the other hand, higher  $V_{E\text{Peak}}$  was associated with lower respiratory symptoms at baseline but higher respiratory symptoms at peak exercise.

In age, sex, height, and BMI-adjusted multivariate modeling that included cardiovascular outputs of exercise that were significantly associated with respiratory symptoms and  $VO_{2\text{Peak}}$  from univariate modeling, only the association of  $O_2$ -Pulse<sub>Peak</sub> with mMRC maintained its significance such that higher  $O_2$ -Pulse<sub>Peak</sub> was significantly associated with the lower likelihood of having an mMRC  $\geq 1$  (average of 35% decrease in odds ratio [OR] for each 1 mL/beat increase in  $O_2$ -Pulse<sub>Peak</sub>;  $P=0.042$ ) (**Table 4**).

In age, sex, height, and BMI-adjusted multivariate modeling that included all cardiovascular and pulmonary outputs of exercise that were significantly associated with respiratory symptoms and  $VO_{2\text{Peak}}$  from univariate modeling, no variable was significantly associated with respiratory symptoms, although  $V_{E\text{Peak}}$  did showed a similar trend of association with respiratory symptoms at rest (direct association with  $\geq 1$  mMRC) and during exercise (inverse with Borg Scale) as in univariate modeling ( $P<0.06$ ) (**Table 5**).

#### **Association of cardiovascular response measures with SHS exposure**

In univariate modeling with adjustment for age, sex, height, and BMI, years cabin SHS exposure was significantly associated with lower exercise capacity as measured by  $VO_{2\text{Peak}}$  and higher respiratory symptoms as measured by FAMRI questionnaire (**Tables 3 and 6**). In

multivariate modeling with inclusion of all cardiovascular outputs, or all cardiovascular and pulmonary outputs, cabin SHS exposure was only significantly associated with higher respiratory symptoms at rest as measured by FAMRI questionnaire (average of 5% and 6% increase in odds ratio [OR] of reporting respiratory symptoms for each one year increase in cabin SHS exposure;  $P \leq 0.018$ ) (**Tables 4 and 5**).

Among the cardiovascular exercise predictors of  $VO_{2Peak}$ , only  $O_2$ -Pulse<sub>Peak</sub> was significantly associated with years of exposure to cabin SHS, showing a parameter estimate of  $-0.036 \pm 0.018$  ( $P=0.043$ ), which indicates a decrease in  $O_2$ -Pulse<sub>Peak</sub> of 0.36 mL/beat for every 10 years of exposure to cabin SHS (**Table 7**). Mediation analysis showed that cabin SHS exposure association with  $VO_{2Peak}$  was mainly (84%) mediated through SHS effect on  $O_2$ -Pulse ( $P=0.034$ ) (**Table 8**).

### **Cardiovascular response measures and baseline air trapping**

Given the physical location of lung, heart, and great vasculature within thoracic cavity, we examined the potential interaction of baseline air trapping and cardiovascular outputs of exercise. To do this, we examined whether the cardiovascular predictors of exercise capacity including  $O_2$ -Pulse (proxy of stroke volume) and  $SBP_{Slope}$  mediate the association of air trapping (FRC/TLC and RV/TLC) with  $VO_{2Peak}$ . These mediation analyses showed a marginally non-significant association of  $O_2$ -Pulse<sub>Peak</sub> with FRC/TLC and RV/TLC (all  $P > 0.05$  and  $< 0.13$ ), which suggested that approximately 60% and 52% of air trapping (FRC/TLC and RV/TLC) effect on  $VO_{2Peak}$  could be mediated through their effect on stroke volume ( $O_2$ -Pulse) (**Table 9**).

### **Discussion**

In this observational study of a never-smoking cohort with a history of remote but prolonged exposure to SHS, we found the cohort to have an abnormal cardiovascular response to exercise that was proportional to their SHS exposure. Volume of oxygen uptake at peak exercise ( $VO_{2Peak}$ ) was associated with years of exposure to SHS, and over 80% of that association was dependent on  $O_2$ -Pulse<sub>Peak</sub>, suggesting that the effect of SHS exposure on exercise capacity to be mainly mediated through SHS effect on stroke volume and cardiac output. We also found suggestive evidence, although not statistically significant ( $P=0.066$ ), that pulmonary air trapping (elevated FRC/TLC and RV/TLC) contribute to lower exercise capacity through its effect on  $O_2$ -Pulse<sub>Peak</sub>, implicating an interacting lung and heart pathophysiology between pulmonary hyperinflation and cardiac output that further impairs exercise capacity (**Figure 2**). Furthermore, we found over 60% of the participants to have a hypertensive response to exercise, suggesting that abnormal escalation of afterload contributed to lower exercise capacity in this SHS-exposed cohort in whom, with the exception of a few (5.4%) with well-controlled hypertension, none had any known cardiovascular disease.

Overall, we found evidence that prolonged exposure to SHS, even when remote, is associated with cardiovascular abnormalities suggestive of occult cardiovascular dysfunction with potential additional contribution from pulmonary hyperinflation. These abnormalities reveal subtle but lower cardiopulmonary functional reserve, manifested here as lower exercise capacity, and implicate a reduced efficiency of body's oxygen delivery machinery, which could be disadvantageous during the times of increased cardiopulmonary output demands as in physiological distress or disease.

In previous studies, we have shown this cohort of never-smokers with history of prolonged remote SHS exposure to have abnormal lung function at rest and abnormal pulmonary

response to exercise including (1) reduced diffusing capacity at rest,<sup>13</sup> (2) reduced pulmonary capillary recruitment (as measured by impaired rise in diffusing capacity) during exercise,<sup>14</sup> (3) decreased small airways airflow indices on spirometry (maximal flow in mid- and end-expiratory airflows [FEF<sub>25-75%</sub> and FEF<sub>75%</sub>]),<sup>13</sup> (4) plethysmographic and radiographic evidence of pulmonary air trapping at rest,<sup>15</sup> and (5) progressive (dynamic) pulmonary hyperinflation during exercise.<sup>15</sup> Overall, these abnormalities are suggestive of presence of an unrecognized early or mild obstructive lung disease that, while not meeting the spirometric definition of COPD, is consistent with an early/mild disease that could be categorized as “pre-COPD” and could contribute to lower pulmonary reserve and potential adverse health outcomes.<sup>43,44</sup>

In the current study, we sought to determine whether there are also subtle cardiovascular abnormalities in this SHS-exposed cohort that are indicative of an occult and/or subclinical cardiovascular disease. Our finding that past exposure to SHS is a predictor of exercise capacity in an O<sub>2</sub>-pulse-dependent (a proxy of stroke volume and cardiac output) manner is novel and suggests that SHS exposure has lasting effect on cardiac function that is observable years after the exposure has ceased, and is consistent with recent findings that long-standing *direct* tobacco smoking impairs cardiac systolic function as evident by an increase in left and right ventricle end-systolic volumes and reduced left and right ejection fractions.<sup>45</sup> Although it remains unclear how exposure to tobacco smoke, *direct* or *indirect*, causes an impairment in cardiac function, an interaction between pulmonary and cardiovascular systems, which occupy the same body cavity (thorax), has been proposed to play a role. Air trapping as measured by lung volumes (FRC/TLC and RV/TLC) is the earliest manifestation of COPD<sup>43,44</sup> and is associated with reduced exercise capacity due to ventilatory limitation caused by progressive air trapping and pulmonary hyperinflation.<sup>15</sup> Changes in lung volumes due to pulmonary hyperinflation could cause

increased intra-thoracic pressures, particularly during exertion, and thus adversely affect the cardiovascular function.<sup>38,46</sup> To investigate this possible mechanism, we examined whether air trapping did contribute to exercise capacity through an interaction with cardiac output by performing a mediation analysis among pulmonary air trapping (FRC/TLC and RV/TLC), cardiac stroke volume ( $O_2$ -pulse), and exercise capacity ( $VO_{2Peak}$ ) (**Figure 2**). Although the analysis did not reach statistical significance ( $P=0.066$  and  $P=0.122$  for FRC/TLC and RV/TLC, respectively) and thus could not provide any further corroborating evidence for our hypothesis, the analysis did suggest that a large proportion (60%) of air trapping effect on  $VO_{2Peak}$  may be mediated through stroke volume. Further research in this area would be needed to better understand the interaction of cardiovascular and pulmonary systems in the context of exposure to direct or indirect smoke.

Another remarkable observation in our study was the common presence of hypertensive response to exercise (HRE). Despite some data to the contrary,<sup>47,48</sup> studies have described HRE in individuals with or without presence of baseline hypertension to be associated with impaired systolic and/or diastolic dysfunction even in the setting of having negative stress test and preserved left ventricular ejection fraction.<sup>49,50</sup> In fact, increasing evidence indicates that HRE is associated with functional and structural heart abnormalities, future development of hypertension, and increased cardiovascular morbidity and mortality.<sup>51-53</sup> In our study, we found a substantial number of participants (62%) to have HRE despite all either having no history of hypertension (95%) or having hypertension that was well-controlled (5%). Studies have reported the prevalence of HRE to be between 3% to 40% among apparently healthy cohorts of varying age, sex, and ethnicity.<sup>54-56</sup> Although we did not observe a significant association between presence of HRE and history of SHS exposure, the high prevalence of HRE among this never-

smoking but SHS-exposed healthy cohort is remarkable, and suggests a potential pathogenetic role for SHS exposure in development of HRE.

## **Limitations**

Our study has limitations that should be kept in view. First, there may be concerns about the generalizability of the findings because the cohort studied are mostly women, which reflects the demographics of those who worked in airlines as flight crew in the latter half of the last century when smoking in aircraft cabin was permitted. The choice to study the flight crew allowed for overcoming the challenge of long-term SHS exposure assessment by providing the ability to generate a more objective and reproducible exposure index based on employment history and the smoking ban timeline on domestic and international flights of different airlines.<sup>13</sup> Women have been reported to be more susceptible to adverse health effects of tobacco smoke.<sup>57</sup> However, at the minimum, the findings should be generalizable to women. Second, the cardiovascular findings reported in this study are mainly derived from CPET with no imaging (such as echocardiography and magnetic resonance imaging [MRI]) or other clinical studies to provide additional robust evidence to corroborate our findings. Such studies are needed and are in progress (ClinicalTrials.gov Identifier: NCT04715568). Nevertheless, studies describing cardiovascular health effects of *direct* smoking using echocardiography and MRI have been previously reported, which corroborate our findings.<sup>58,59</sup> Our report however is the first report that describes the chronic and long-term cardiovascular health effects due to past prolonged exposure to SHS. Third, while we found association of exercise capacity ( $VO_{2Peak}$ ) with years of SHS exposure, the association of respiratory symptoms with SHS was less striking and less consistent across the different questionnaire platforms. However, it is not uncommon to see differences in scores across different respiratory questionnaires,<sup>60</sup> and similarly, baseline

respiratory symptoms (mMRC and FAMRI questionnaires) may measure different things and thus produce different scores compared to those done at peak exercise (Borg Scale). For example, subjects who had impairments at baseline and thus were more symptomatic are likely to not perform as well during the exercise and thus may report lesser symptoms in a sub-maximal effort exercise test.

## **Conclusion**

Healthy never-smokers with history of remote but prolonged exposure to SHS have an abnormal cardiovascular response to exercise, which is characterized by a stroke volume (oxygen-pulse) and thus an exercise capacity that are reduced proportional to their years of exposure to SHS. The mechanisms by which past exposure to SHS may limit stroke volume and thus exercise capacity is unknown, but pulmonary hyperinflation may have a contributory effect beyond its role in ventilatory limitation. Furthermore, these SHS-exposed individuals have a considerably higher prevalence of hypertensive response to exercise than that reported in healthy general population. Overall, the abnormal cardiovascular response to exercise in this population reveals the presence of an occult or subclinical pathology that impairs the cardiopulmonary functional reserve and reduces the efficiency of body's oxygen delivery machinery, which could be disadvantageous during the times of increased cardiopulmonary output demands as in physiological distress or disease.

## REFERENCES

1. Centers for Disease Control and Prevention. Vital Signs: Disparities in Nonsmokers' Exposure to Secondhand Smoke - United States, 1999–2012. 2015; [https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6404a7.htm?s\\_cid=mm6404a7\\_w](https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6404a7.htm?s_cid=mm6404a7_w). Accessed November 28, 2018.
2. Collaborators GBDT. Smoking prevalence and attributable disease burden in 195 countries and territories, 1990-2015: a systematic analysis from the Global Burden of Disease Study 2015. *Lancet*. 2017;389(10082):1885-1906.
3. Tsai J, Homa DM, Gentzke AS, et al. Exposure to Secondhand Smoke Among Nonsmokers - United States, 1988-2014. *MMWR Morb Mortal Wkly Rep*. 2018;67(48):1342-1346.
4. Barnoya J, Glantz SA. Cardiovascular effects of secondhand smoke: nearly as large as smoking. *Circulation*. 2005;111(20):2684-2698.
5. Meyers DG, Neuberger JS, He J. Cardiovascular effect of bans on smoking in public places: a systematic review and meta-analysis. *J Am Coll Cardiol*. 2009;54(14):1249-1255.
6. Yankelevitz DF, Henschke CI, Yip R, et al. Second-hand tobacco smoke in never smokers is a significant risk factor for coronary artery calcification. *JACC Cardiovasc Imaging*. 2013;6(6):651-657.
7. . *The Health Consequences of Involuntary Exposure to Tobacco Smoke: A Report of the Surgeon General*. Atlanta (GA)2006.
8. . *The Health Consequences of Smoking-50 Years of Progress: A Report of the Surgeon General*. Atlanta (GA)2014.
9. . *Secondhand Smoke Exposure and Cardiovascular Effects: Making Sense of the Evidence*. Washington (DC)2010.
10. Repace J. Flying the smoky skies: secondhand smoke exposure of flight attendants. *Tob Control*. 2004;13 Suppl 1:i8-19.
11. Benowitz NL, Bernert JT, Caraballo RS, Holiday DB, Wang J. Optimal serum cotinine levels for distinguishing cigarette smokers and nonsmokers within different racial/ethnic groups in the United States between 1999 and 2004. *Am J Epidemiol*. 2009;169(2):236-248.
12. Arjomandi M, Haight T, Redberg R, Gold WM. Pulmonary function abnormalities in never-smoking flight attendants exposed to secondhand tobacco smoke in the aircraft cabin. *J Occup Environ Med*. 2009;51(6):639-646.
13. Arjomandi M, Haight T, Redberg R, Gold WM. Pulmonary function abnormalities in never-smoking flight attendants exposed to secondhand tobacco smoke in the aircraft cabin. *J Occup Environ Med*. 2009;51(6):639-646.
14. Arjomandi M, Haight T, Sadeghi N, Redberg R, Gold WM. Reduced exercise tolerance and pulmonary capillary recruitment with remote secondhand smoke exposure. *PLoS One*. 2012;7(4):e34393.
15. Arjomandi M, Zeng S, Geerts J, et al. Lung volumes identify an at-risk group in persons with prolonged secondhand tobacco smoke exposure but without overt airflow obstruction. *BMJ Open Respir Res*. 2018;5(1):e000284.

16. Eisner MD, Wang Y, Haight TJ, Balmes J, Hammond SK, Tager IB. Secondhand smoke exposure, pulmonary function, and cardiovascular mortality. *Ann Epidemiol*. 2007;17(5):364-373.
17. van Koeverden I, Blanc PD, Bowler RP, Arjomandi M. Secondhand Tobacco Smoke and COPD Risk in Smokers: A COPD Gene Study Cohort Subgroup Analysis. *COPD*. 2015;12(2):182-189.
18. Standardization of Spirometry, 1994 Update. American Thoracic Society. *Am J Respir Crit Care Med*. 1995;152(3):1107-1136.
19. Macintyre N, Crapo RO, Viegi G, et al. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. *Eur Respir J*. 2005;26(4):720-735.
20. Miller MR, Crapo R, Hankinson J, et al. General considerations for lung function testing. *Eur Respir J*. 2005;26(1):153-161.
21. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. *Eur Respir J*. 2005;26(2):319-338.
22. Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. *Eur Respir J*. 2005;26(5):948-968.
23. Wanger J, Clausen JL, Coates A, et al. Standardisation of the measurement of lung volumes. *Eur Respir J*. 2005;26(3):511-522.
24. Comroe Jr. JH. Pulmonary Function Tests. *Methods in Medical Research*. Chicago, Illinois: Year Book Publishers, Inc.; 1950:188.
25. Mitchell MM, Renzetti AD, Jr. Evaluation of a single-breath method of measuring total lung capacity. *Am Rev Respir Dis*. 1968;97(4):571-580.
26. Burns CB, Scheinhorn DJ. Evaluation of single-breath helium dilution total lung capacity in obstructive lung disease. *Am Rev Respir Dis*. 1984;130(4):580-583.
27. Dubois AB, Botelho SY, Bedell GN, Marshall R, Comroe JH, Jr. A rapid plethysmographic method for measuring thoracic gas volume: a comparison with a nitrogen washout method for measuring functional residual capacity in normal subjects. *J Clin Invest*. 1956;35(3):322-326.
28. Dubois AB, Botelho SY, Comroe JH, Jr. A new method for measuring airway resistance in man using a body plethysmograph: values in normal subjects and in patients with respiratory disease. *J Clin Invest*. 1956;35(3):327-335.
29. Briscoe WA, Dubois AB. The relationship between airway resistance, airway conductance and lung volume in subjects of different age and body size. *J Clin Invest*. 1958;37(9):1279-1285.
30. Blakemore WS, Forster RE, Morton JW, Ogilvie CM. A standardized breath holding technique for the clinical measurement of the diffusing capacity of the lung for carbon monoxide. *J Clin Invest*. 1957;36(1 Part 1):1-17.
31. Beaver WL, Wasserman K, Whipp BJ. A new method for detecting anaerobic threshold by gas exchange. *J Appl Physiol*. 1986;60(6):2020-2027.
32. Wasserman K, Hansen JE, Sue DY, BJ W. *Principles of Exercise Testing and Interpretation*. Philadelphia: Lea & Febiger; 1987.
33. Borg G. *Borg's perceived exertion and pain scales*. Champaign, IL, US: Human Kinetics; 1998.
34. Fletcher CM, Elmes PC, Fairbairn AS, Wood CH. The significance of respiratory symptoms and the diagnosis of chronic bronchitis in a working population. *British medical journal*. 1959;2(5147):257-266.

35. Quanjer PH, Stanojevic S, Cole TJ, et al. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. *Eur Respir J*. 2012;40(6):1324-1343.
36. Stocks J, Quanjer PH. Reference values for residual volume, functional residual capacity and total lung capacity. ATS Workshop on Lung Volume Measurements. Official Statement of The European Respiratory Society. *Eur Respir J*. 1995;8(3):492-506.
37. Wasserman K, Hansen J, Sue D, Stringer W, Whipp B. *Principles of Exercise Testing and Interpretation*. 4th edition ed: Lippincott Williams & Wilkins, Philadelphia, USA.; 2004.
38. Watz H. The Lungs and the Heart. *American Journal of Respiratory and Critical Care Medicine*. 2015;192(1):7-8.
39. Smith BM, Kawut SM, Bluemke DA, et al. Pulmonary Hyperinflation and Left Ventricular Mass. *Circulation*. 2013;127(14):1503-1511.
40. Cuttica MJ, Colangelo LA, Shah SJ, et al. Loss of Lung Health from Young Adulthood and Cardiac Phenotypes in Middle Age. *American Journal of Respiratory and Critical Care Medicine*. 2015;192(1):76-85.
41. Butler J, Schrijen F, Henriquez A, Polu J-M, Albert RK. Cause of the Raised Wedge Pressure on Exercise in Chronic Obstructive Pulmonary Disease. *American Review of Respiratory Disease*. 1988;138(2):350-354.
42. Tingley D, Yamamoto T, Hirose K, Keele L, Imai K. mediation: R Package for Causal Mediation Analysis. 2014. 2014;59(5):38.
43. Arjomandi M, Zeng S, Barjaktarevic I, et al. Radiographic Lung Volumes Predict Progression to COPD in Smokers with Preserved Spirometry in SPIROMICS. *Eur Respir J*. 2019.
44. Zeng S, Tham A, Bos B, Jin J, Giang B, Arjomandi M. Lung volume indices predict morbidity in smokers with preserved spirometry. *Thorax*. 2018.
45. Hendriks T, van Dijk R, Alsabaan NA, van der Harst P. Active Tobacco Smoking Impairs Cardiac Systolic Function. *Scientific Reports*. 2020;10(1):6608.
46. Cuttica MJ, Colangelo LA, Shah SJ, et al. Loss of Lung Health from Young Adulthood and Cardiac Phenotypes in Middle Age. *American Journal of Respiratory and Critical Care Medicine*. 2015;192(1):76-85.
47. Fagard R, Staessen J, Thijs L, Amery A. Prognostic significance of exercise versus resting blood pressure in hypertensive men. *Hypertension*. 1991;17(4):574-578.
48. Fagard RH, Pardaens K, Staessen JA, Thijs L. Prognostic value of invasive hemodynamic measurements at rest and during exercise in hypertensive men. *Hypertension*. 1996;28(1):31-36.
49. Mottram PM, Haluska B, Yuda S, Leano R, Marwick TH. Patients with a hypertensive response to exercise have impaired systolic function without diastolic dysfunction or left ventricular hypertrophy. *J Am Coll Cardiol*. 2004;43(5):848-853.
50. Takamura T, Onishi K, Sugimoto T, et al. Patients with a hypertensive response to exercise have impaired left ventricular diastolic function. *Hypertens Res*. 2008;31(2):257-263.
51. Filipovsky J, Ducimetiere P, Safar ME. Prognostic significance of exercise blood pressure and heart rate in middle-aged men. *Hypertension*. 1992;20(3):333-339.

52. Manolio TA, Burke GL, Savage PJ, Sidney S, Gardin JM, Oberman A. Exercise blood pressure response and 5-year risk of elevated blood pressure in a cohort of young adults: the CARDIA study. *Am J Hypertens*. 1994;7(3):234-241.
53. Tsumura K, Hayashi T, Hamada C, Endo G, Fujii S, Okada K. Blood pressure response after two-step exercise as a powerful predictor of hypertension: the Osaka Health Survey. *J Hypertens*. 2002;20(8):1507-1512.
54. Le VV, Mitiku T, Sungar G, Myers J, Froelicher V. The blood pressure response to dynamic exercise testing: a systematic review. *Prog Cardiovasc Dis*. 2008;51(2):135-160.
55. Scott JA, Coombes JS, Prins JB, Leano RL, Marwick TH, Sharman JE. Patients with type 2 diabetes have exaggerated brachial and central exercise blood pressure: relation to left ventricular relative wall thickness. *Am J Hypertens*. 2008;21(6):715-721.
56. Kramer CK, Leitão CB, Canani LH, Ricardo ED, Pinto LC, Gross JL. Blood pressure responses to exercise in type II diabetes mellitus patients with masked hypertension. *J Hum Hypertens*. 2009;23(9):620-622.
57. Allen AM, Oncken C, Hatsukami D. Women and Smoking: The Effect of Gender on the Epidemiology, Health Effects, and Cessation of Smoking. *Curr Addict Rep*. 2014;1(1):53-60.
58. Kamimura D, Cain LR, Mentz RJ, et al. Cigarette Smoking and Incident Heart Failure. *Circulation*. 2018;137(24):2572-2582.
59. Nadruz W, Claggett B, Gonçalves A, et al. Smoking and Cardiac Structure and Function in the Elderly. *Circulation: Cardiovascular Imaging*. 2016;9(9):e004950.
60. Rutten-van Mülken M, Roos B, Van Noord JA. An empirical comparison of the St George's Respiratory Questionnaire (SGRQ) and the Chronic Respiratory Disease Questionnaire (CRQ) in a clinical trial setting. *Thorax*. 1999;54(11):995-1003.
61. Crapo RO, Morris AH, Gardner RM. Reference values for pulmonary tissue volume, membrane diffusing capacity, and pulmonary capillary blood volume. *Bull Eur Physiopathol Respir*. 1982;18(6):893-899.

## FIGURE LEGENDS

**Figure 1- Subject flow.** Abbreviations- SHS=secondhand tobacco smoke; PFT= pulmonary function test; FEV1= forced expiratory volume in 1 second; FVC= forced vital capacity; BMI= body mass index;  $VO_{2Max}$ = volume of maximum oxygen uptake.

**Figure 2- Proposed model referenced in the discussion.** Illustration of mediation effects between SHS exposure and exercise capacity. Abbreviations- SV= cardiac stroke volume; HRE= hypertensive response to exercise; HR= heart rate; SHS=secondhand tobacco smoke; VC= vital capacity; IC= inspiratory capacity;  $V_E$ = minute ventilation;  $V_T$ = volume of tidal breathing.

## TABLES

**Table 1- Subject characteristics.**

Subject characteristics	N=166
<b>Demographics and anthropetrics</b>	
Age (years)	54.3±11.4
Female sex [n (%)]	150 (90.4%)
Height (cm)	165.8±6.5
Weight (kg)	64.7±9.8
BMI (kg/m <sup>2</sup> )	23.4±3.0
Smoking history (pack-years) [min-max]	0-0.7
History of hypertension [n (%)]	8
<b>SHS Exposure</b>	
Ever Cabin SHS exposure [n (%)]	90 (54.2%)
Cabin SHS exposure among exposed (years)	16.8±8.8
Time since last cabin SHS exposure (years)	17.4±6.9
Any form of non-cabin SHS exposure [n/N (%)]	122/131 (93.1%)
Childhood home SHS exposure [n/N (%)]	82/131 (62.6%)
Adult home SHS exposure [n/N (%)]	46/131 (35.1%)
Non-airline occupational SHS exposure [n/N (%)]	49/131 (37.4%)
Other SHS Exposure [n/N (%)]	87/131 (66.4%)
<b>Symptoms</b>	
mMRC Dyspnea Scale ≥1 [n (%)]	19 (11.4%)
Subjects with any respiratory symptoms [n (%)]	80 (48.2%)
Subjects ever experiencing shortness of breath [n (%)]	21 (12.7%)
Subjects with cough ≥2 episodes/year [n (%)]	70 (42.2%)
Subjects with less activity than peers [n (%)]	5 (3.0%)

<b>Pulmonary Function Tests</b>	
FEV <sub>1</sub> (% predicted)	104±12
FVC (% predicted)	107±13
FEV <sub>1</sub> /FVC	78±4
FEV <sub>1</sub> /FVC (% predicted)	97±4
FEF <sub>25-75</sub> (% predicted)	98±23
FEF <sub>75</sub> (% predicted)	118±42
D <sub>LCO</sub> adjusted for Hgb (mL/min/mmHg)	22.03±4.57
D <sub>LCO</sub> adjusted for Hgb (% predicted)	79±10
D <sub>L</sub> /V <sub>A</sub> adjusted for Hgb (mL/min/mmHg/L)	4.43±0.67
D <sub>L</sub> /V <sub>A</sub> adjusted for Hgb (% predicted)	124±16
Alveolar volume (V <sub>A</sub> ) (L)	4.98±0.81
Alveolar volume (V <sub>A</sub> ) (L) (% predicted)	95±11
TLC (% predicted)	102±10
RV (% predicted)	95±17
RV/TLC	34±7
RV/TLC (% predicted)	90±12
FRC (% predicted)	102±20
FRC/TLC	53±8
FRC/TLC (% predicted)	99±14

Footnote: Demographics, secondhand smoke (SHS) exposure, symptoms, and lung function in subjects with preserved spirometry that underwent exercise testing. Other SHS exposure was defined as non-aircraft cabin SHS exposure outside the work or home environment such as in recreational public places. Data are presented as mean±standard deviation or number of subjects with positive value for the variable (n) out of the total number of subjects (N) and percentage of

subjects (%). Reference equations: percent predicted of normal values of spirometry, diffusing capacity, and lung volumes were calculated using Global Lung Function Initiative (GLI), Crapo, and Quanjar predicted formulas, respectively.<sup>35-37,61</sup> Abbreviations- BMI: body mass index; FEV<sub>1</sub>: forced expiratory volume in 1 second; FVC: forced vital capacity; FEF<sub>25-75</sub>: maximum airflow at mid-lung volume; FEF<sub>75</sub>: maximum airflow at low-lung volume; TLC: total lung capacity; RV: residual volume; FRC: functional residual capacity; DcoSB: single-breath diffusing capacity of carbon monoxide; Hgb: hemoglobin; mMRC: modified medical research council.

**Table 2- Cardiopulmonary testing measurements.**

<b>Cardiopulmonary exercise testing outputs</b>	<b>N=166</b>
Cardiopulmonary Testing Measurements	
VO <sub>2Peak</sub> (L/min)	1.52±0.43
VO <sub>2Peak</sub> (% predicted)	100±23
Reached 100% predicted VO <sub>2Peak</sub> [n (%)]	75 (45.2%)
VO <sub>2Peak</sub> /kg (mL/min.kg)	23.66±6.37
VCO <sub>2Peak</sub> (L/min)	1.84±0.54
Watts <sub>Peak</sub> (watts)	153±44
Watts <sub>Peak</sub> (% predicted)	116±31
Watts per stage (watts)	26±7
Stages completed	6±1.2
Length of exercise (min)	11.9±2.5
Symptoms at peak exercise (Borg Scale 0 to 10)	
Shortness of Breath	4.1±1.9
Effort	5.1±2.0
Fatigue	4.6±1.9
Pulmonary Response	
V <sub>EPeak</sub> (L/min)	56.07±14.96
V <sub>EPeak</sub> (% predicted)	114±26
RER	1.22±0.14
RR <sub>Peak</sub> (breaths/min)	35.0±9.0
V <sub>TPeak</sub> (L)	1.68±0.41
V <sub>TPeak</sub> (% predicted)	85±16
V <sub>E</sub> /VO <sub>2Peak</sub>	37.53±6.38
V <sub>E</sub> /VCO <sub>2Peak</sub>	30.86±4.13

$V_E/VCO_{2Peak}$ (% predicted)	109±11
$V_E/VCO_{2Lowest}$	29.42±4.5
$V_E/VCO_{2Lowest}$ (% predicted)	105±20
$VO_2$ at Anaerobic Threshold ( $VO_{2AT}$ ) (L/min)	0.98±0.31
$VO_2$ at Anaerobic Threshold ( $VO_{2AT}$ ) (% predicted)	65±16
$V_E/VCO_2$ at Anaerobic Threshold	31.57±3.95
$V_E/VCO_2$ at Anaerobic Threshold (% predicted)	112±12
Cardiovascular Response	
$HR_{Baseline}$ (beat/min)	67±12
$HR_{Peak}$ (beat/min)	143±18
$HR_{Slope}$ (beat/min/Watt)	0.50±0.14
$SBP_{Baseline}$ (mmHg)	122±16
$SBP_{Peak}$ (mmHg)	176±20
$SBP_{Slope}$ (mmHg/Watt)	0.39±0.16
$DBP_{Baseline}$ (mmHg)	77±9
$DBP_{Peak}$ (mmHg)	93±10
$DBP_{Slope}$ (mmHg/Watt)	0.12±0.08
HRE (met at least one criterion) [n/N (%)]	98/158 (62%)
Rise in SBP ≥50 mmHg (≥60 mmHg for men)	91/159 (57.2%)
$SBP_{Peak} \geq 190$ mmHg (≥210 mmHg for men)	27/159 (17%)
$DBP_{Peak} \geq 105$ mmHg	15/158 (9.5%)
$O_2$ -Pulse $_{Peak}$ (mL/beat)	10.6±2.8
$O_2$ -Pulse $_{Peak}$ (% predicted)	117±25
Reached 100% predicted $O_2$ -Pulse $_{Peak}$ [n (%)]	123 (74.1%)
$O_2$ -Pulse $_{Baseline}$ (mL/beat)	3.7±1.0
$O_2$ -Pulse $_{Slope}$ (mL/beat/Watt)	0.05±0.01

O <sub>2</sub> -Pulse at Anaerobic Threshold (L/beat)	8.7±2.6
O <sub>2</sub> -Pulse at Anaerobic Threshold (% predicted)	73±26

Footnote: Cardio-pulmonary measurements in subjects who underwent exercise testing. Data are presented as mean ± standard deviation. Data are presented as mean ± standard deviation.

Reference equations: percent predicted of normal values of cardiopulmonary outputs were calculated using Wassermann predicted formulas.<sup>37</sup> Abbreviations- VO<sub>2Peak</sub>: peak oxygen uptake; VO<sub>2Max.kg</sub>: peak oxygen uptake per kilogram of body weight; Watts<sub>Peak</sub>: peak work stage completed in watts; VCO<sub>2Peak</sub>: peak carbon dioxide production; O<sub>2</sub>-Pulse<sub>Peak</sub>: oxygen uptake per heartbeat at peak exercise; VE<sub>Peak</sub>: peak minute ventilation value; RER: respiratory exchange ratio (VCO<sub>2</sub>/VO<sub>2</sub>) at peak exercise; RR<sub>Peak</sub>: peak respiratory rate; VT<sub>Peak</sub>: peak tidal volume; HR<sub>Peak</sub>: peak heart rate.

**Table 3- Associations of VO<sub>2Peak</sub> (outcome) with each of the cardiopulmonary exercise outputs and SHS exposure (predictors).**

Univariate modeling as a predictor for VO <sub>2Peak</sub> (mL/s)	N	Estimate±SEM	95% CI	P-value
<b>Cardiovascular predictors</b>				
<b>Peaks</b>				
<b>O<sub>2</sub>-Pulse<sub>Peak</sub></b>	<b>166</b>	<b>127.2±7.0</b>	<b>(113.4 to 141.0)</b>	<b>&lt;0.001</b>
<b>HR<sub>Peak</sub></b>	<b>166</b>	<b>7.7±1.3</b>	<b>(5.0 to 10.3)</b>	<b>&lt;0.001</b>
SBP <sub>Peak</sub>	159	2.5±1.4	(-0.3 to 5.3)	0.079
DBP <sub>Peak</sub>	158	0.2±2.8	(-5.2 to 5.7)	0.935
<b>Slopes</b>				
O <sub>2</sub> -Pulse <sub>Slope</sub>	164	1820.4±2314.4	(-2751.0 to 6391.9)	0.432
<b>HR<sub>Slope</sub></b>	<b>164</b>	<b>-677.5±208.6</b>	<b>(-1089.6 to -265.4)</b>	<b>0.001</b>
<b>SBP<sub>Slope</sub></b>	<b>159</b>	<b>-567.9±175.5</b>	<b>(-914.6 to -221.2)</b>	<b>0.001</b>
<b>DBP<sub>Slope</sub></b>	<b>159</b>	<b>-1394.3±325.1</b>	<b>(-2036.6 to -752.1)</b>	<b>&lt;0.001</b>
<b>HRE (met at least one criterion)</b>	<b>158</b>	<b>197.7±50.5</b>	<b>(97.8 to 297.5)</b>	<b>&lt;0.001</b>
<b>Pulmonary predictors</b>				
<b>RR<sub>Peak</sub> (same as F)</b>	<b>160</b>	<b>17.4±2.5</b>	<b>(12.4 to 2.4)</b>	<b>&lt;0.001</b>
<b>VE<sub>Peak</sub> (VT * RR)</b>	<b>166</b>	<b>17.6±1.2</b>	<b>(15.3 to 19.9)</b>	<b>&lt;0.001</b>
<b>VT<sub>Peak</sub> (tidal volume)</b>	<b>161</b>	<b>392.8±79.9</b>	<b>(235.0 to 550.6)</b>	<b>&lt;0.001</b>
VE/VCO <sub>2Peak</sub>	166	-10.6±6.6	(-23.7 to 2.4)	0.109
<b>RV/TLC (baseline)</b>	<b>166</b>	<b>-15.0±6.4</b>	<b>(-27.6 to -2.3)</b>	<b>0.020</b>
<b>FRC/TLC (baseline)</b>	<b>158</b>	<b>-10.6±4.5</b>	<b>(-19.4 to -1.7)</b>	<b>0.019</b>
<b>Exposure predictors</b>				
<b>Airline SHS exposure (years)</b>	<b>166</b>	<b>-5.5±2.7</b>	<b>(-10.9 to -0.03)</b>	<b>0.048</b>
Childhood home SHS exposure (Y/N)	130	-23.5±62.0	(-146.3 to 99.2)	0.705
Adult home SHS exposure (Y/N)	130	-36.4±65.5	(-166.1 to 93.3)	0.579
Non-airline occupational SHS exposure (Y/N)	128	86.7±62.3	(-36.6 to 210.0)	0.166

Footnote: Associations of VO<sub>2Peak</sub> (outcome) with each of the cardiopulmonary exercise outputs and SHS exposure (predictors) were assessed by univariate linear regression models with adjustment for age, sex, height, BMI, and corresponding baseline values (for slope predictors). Results for significant predictors are shown in bold. Abbreviations- VO<sub>2Peak</sub>: peak oxygen uptake; SHS: secondhand smoke, O<sub>2</sub>-Pulse<sub>Peak</sub>: oxygen uptake per heartbeat at peak exercise;

HR: heart rate; SBP: systolic blood pressure; DBP: diastolic blood pressure; HRE: hypertensive response to exercise based on at least one criterion;  $RR_{Peak}$ : peak respiratory rate;  $VE_{Peak}$ : peak minute ventilation value;  $VT_{Peak}$ : peak tidal volume; RV: residual volume; TLC: total lung capacity; FRC: functional residual capacity.

**Table 4- Association of VO<sub>2Peak</sub> or respiratory symptoms (outcome) with cardiovascular exercise outputs from multivariate modeling.**

<b>Multivariate modeling</b>	<b>Estimate±SEM</b>	<b>95% CI</b>	<b>P value</b>
<b>VO<sub>2Peak</sub> (mL/s)</b>	N=158		
<b>O<sub>2</sub>-Pulse<sub>Peak</sub></b>	<b>156.3±8.0</b>	<b>140.4 to 172.1</b>	<b>&lt;0.001</b>
<b>HR<sub>Slope</sub></b>	<b>892.1±135.3</b>	<b>624.6 to 1159.6</b>	<b>&lt;0.001</b>
<b>SBP<sub>Slope</sub></b>	<b>-247.4±99.6</b>	<b>-444.2 to -50.6</b>	<b>0.014</b>
DBP <sub>Slope</sub>	-326.0±196.4	-714.2 to 62.1	0.099
SHS exposure	-1.2±1.5	-4.1 to 1.8	0.427
<b>Borg scale</b>	N=158		
<b>O<sub>2</sub>-Pulse<sub>Peak</sub></b>	0.07±0.1	-0.12 to 0.26	0.477
<b>HR<sub>Slope</sub></b>	0.45±1.61	-2.73 to 3.62	0.782
<b>SBP<sub>Slope</sub></b>	-1.07±1.18	-3.41 to 1.26	0.365
<b>DBP<sub>Slope</sub></b>	-1.62±2.33	-6.23 to 2.99	0.489
<b>SHS exposure</b>	-0.01±0.02	-0.05 to 0.02	0.530
<b>Multivariate modeling</b>	<b>Odds ratio±SEM</b>	<b>95% CI</b>	<b>P value</b>
<b>Having mMRC≥1</b>	N=158		
<b>O<sub>2</sub>-Pulse<sub>Peak</sub></b>	<b>0.65±0.14</b>	<b>0.41 to 0.96</b>	<b>0.042</b>
HR <sub>Slope</sub>	0.95±2.68	0.002 to 218.96	0.986
SBP <sub>Slope</sub>	23.65±57.74	0.20 to 3190.17	0.195
DBP <sub>Slope</sub>	0.22±0.87	0.0001 to 504.07	0.703
SHS exposure	1.04±0.04	0.96 to 1.12	0.346
<b>Having any respiratory symptoms</b>	N=158		
O <sub>2</sub> -Pulse <sub>Peak</sub>	0.81±0.09	0.64 to 1.005	0.061
HR <sub>Slope</sub>	0.08±0.15	0.002 to 2.87	0.176
SBP <sub>Slope</sub>	2.65±3.65	0.18 to 41.55	0.478
DBP <sub>Slope</sub>	1.02±2.74	0.01 to 197.46	0.993
<b>SHS exposure</b>	<b>1.06±0.02</b>	<b>1.02 to 1.10</b>	<b>0.007</b>

**Footnote:** Associations of VO<sub>2Peak</sub> or respiratory symptoms (outcome) with cardiopulmonary exercise outputs and SHS exposure (predictors) were assessed by multivariate linear regression models with adjustment for age, sex, height, BMI, and corresponding baseline values (baseline HR, SBP, and DBP). Results for significant predictors are shown in bold. Abbreviations- VO<sub>2Peak</sub>: peak oxygen uptake; SHS: secondhand smoke, O<sub>2</sub>-Pulse<sub>Peak</sub>: oxygen uptake per heartbeat at peak exercise; HR: heart rate; SBP: systolic blood pressure; DBP: diastolic blood pressure.

**Table 5- Associations of VO<sub>2</sub>Peak or respiratory symptoms (outcome) with cardiovascular and pulmonary outputs from multivariate modeling.**

<b>Multivariate modeling</b>	<b>Estimate±SEM</b>	<b>95% CI</b>	<b>P value</b>
<b>VO<sub>2</sub>Peak (mL/s)</b>			
N=153			
<b>O2-Pulse<sub>Peak</sub></b>	<b>113.5±7.9</b>	<b>98.0 to 129.1</b>	<b>&lt;0.001</b>
<b>HR<sub>Slope</sub></b>	<b>458.3±117.9</b>	<b>225.1 to 691.5</b>	<b>&lt;0.001</b>
<b>SBP<sub>Slope</sub></b>	<b>-171.2±77.5</b>	<b>-324.4 to -18.0</b>	<b>0.028</b>
DBP <sub>Slope</sub>	-107.4±1510	-406.1 to 191.2	0.478
RR <sub>Peak</sub>	-4.4±2.6	-9.5 to 0.7	0.086
<b>VE<sub>Peak</sub></b>	<b>11.3±1.8</b>	<b>7.7 to 14.9</b>	<b>&lt;0.001</b>
VT <sub>Peak</sub>	-27.4±60.5	-147.0 to 92.3	0.651
SHS exposure	-0.7±1.2	-3.0 to 1.6	0.566
FRC/TLC	0.6±1.8	-3.0 to 4.2	0.745
<b>Borg scale</b>			
N=153			
O2-Pulse <sub>Peak</sub>	-0.08±0.12	-0.32 to 0.17	0.532
HR <sub>Slope</sub>	-1.49±1.85	-5.15 to 2.18	0.423
SBP <sub>Slope</sub>	-0.66±1.22	-3.07 to 1.74	0.585
DBP <sub>Slope</sub>	-0.82±2.37	-5.51 to 3.87	0.730
RR <sub>Peak</sub>	-0.04±0.04	-0.12 to 0.04	0.318
VE <sub>Peak</sub>	0.06±0.03	-0.001 to 0.11	0.054
VT <sub>Peak</sub>	-0.56±0.95	-2.44 to 1.32	0.554
SHS exposure	-0.0050±0.02	-0.04 to 0.03	0.789
FRC/TLC	0.01±0.03	-0.05 to 0.07	0.763
<b>Multivariate modeling</b>	<b>Odds ratio±SEM</b>	<b>95% CI</b>	<b>P value</b>
<b>Having mMRC≥1</b>			
N=153			
O2-Pulse <sub>Peak</sub>	0.75±0.20	0.42 to 1.24	0.280
HR <sub>Slope</sub>	4.16±13.77	0.004 to 2815.3	0.666
SBP <sub>Slope</sub>	7.95±20.53	0.05 to 1520.08	0.422
DBP <sub>Slope</sub>	0.06±0.24	9.90e-6 to 214.9	0.496
RR <sub>Peak</sub>	1.17±0.09	0.999 to 1.38	0.051
VE <sub>Peak</sub>	0.88±0.06	0.77 to 0.997	0.056
VT <sub>Peak</sub>	7.54±13.48	0.21 to 267.35	0.258
SHS exposure	1.06±0.04	0.97 to 1.15	0.200
FRC/TLC	1.09±0.06	0.97 to 1.23	0.159
<b>Having any respiratory symptoms</b>			
N=153			
O2-Pulse <sub>Peak</sub>	0.86±0.12	0.65 to 1.13	0.290
HR <sub>Slope</sub>	0.10±0.22	0.001 to 6.41	0.288
SBP <sub>Slope</sub>	2.34±3.31	0.15 to 39.62	0.547
DBP <sub>Slope</sub>	0.96±2.62	0.004 to 210.53	0.987
RR <sub>Peak</sub>	0.999±0.05	0.91 to 1.10	0.992
VE <sub>Peak</sub>	0.996±0.03	0.93 to 1.06	0.902
VT <sub>Peak</sub>	0.69±0.76	0.08 to 6.24	0.734
<b>SHS exposure</b>	<b>1.05±0.02</b>	<b>1.01 to 1.10</b>	<b>0.018</b>

FRC/TLC	1.02±0.03	0.96 to 1.09	0.475
---------	-----------	--------------	-------

Footnote: Associations of  $VO_{2Peak}$  or respiratory symptoms (outcome) with cardiopulmonary exercise outputs and SHS exposure (predictors) were assessed by multivariate linear regression models with adjustment for age, sex, height, BMI, and corresponding baseline values (baseline HR, SBP, and DBP). The subjects' symptoms and activity level were scored according to the Borg scale, mMRC, and the FAMRI questionnaire (whether they have ever reported shortness of breath, cough  $\geq 2$  episodes/year or less activity than peers). Results for significant predictors are shown in bold. Abbreviations-  $VO_{2Peak}$ : peak oxygen uptake; SHS: secondhand smoke,  $O_2$ -Pulse<sub>Peak</sub>: oxygen uptake per heartbeat at peak exercise; HR: heart rate; SBP: systolic blood pressure; DBP: diastolic blood pressure; RR<sub>Peak</sub>: peak respiratory rate; VE<sub>Peak</sub>: peak minute ventilation value; VT<sub>Peak</sub>: peak tidal volume; RV: residual volume; TLC: total lung capacity; FRC: functional residual capacity.

**Table 6- Associations of respiratory symptoms (outcome) with each of the cardiopulmonary exercise outputs and SHS exposure (predictors).**

Predictors	Univariate modeling for Borg scale			Univariate modeling for having mMRC≥1			Univariate modeling for having any respiratory symptoms		
	N	Estimate±SEM 95% CI	P value	N	Odds Ratio±SEM 95% CI	P value	N	Odds Ratio ±SEM 95% CI	P value
<b>Cardiovascular predictors</b>									
<b>Peaks</b>									
<b>O<sub>2</sub>-Pulse<sub>Peak</sub></b>	163	0.09±0.07 (-0.05 to 0.24)	0.218	<b>166</b>	<b>0.72±0.11</b> <b>(0.52 to 0.96)</b>	<b>0.031</b>	166	0.9±0.07 (0.76 to 1.05)	0.174
<b>HR<sub>Peak</sub></b>	<b>163</b>	<b>0.02±0.01</b> <b>(0.01 to 0.04)</b>	<b>0.005</b>	166	0.98±0.01 (0.95 to 1.01)	0.241	166	0.99±0.01 (0.97 to 1.01)	0.270
<b>SBP<sub>Peak</sub></b>	158	0.01±0.01 (-0.01 to 0.03)	0.289	159	1.002±0.02 (0.97 to 1.03)	0.895	159	1.003±0.01 (0.99 to 1.02)	0.737
<b>DBP<sub>Peak</sub></b>	157	0.01±0.02 (-0.02 to 0.04)	0.539	158	0.96±0.03 (0.9 to 1.02)	0.229	158	0.98±0.02 (0.95 to 1.02)	0.319
<b>Slopes</b>									
<b>O<sub>2</sub>-Pulse<sub>Slope</sub></b>	<b>163</b>	<b>-29.01±14.06</b> <b>(-56.78 to -1.24)</b>	<b>0.040</b>	164	6.18e10±1.37e12 (6.29e-10 to 7.53e29)	0.262	164	1.53e-12±2.47e-11 (6.93e27 to 31.28)	0.091
<b>HR<sub>Slope</sub></b>	163	-1.23±1.29 (-3.77 to 1.31)	0.341	164	7.47±78.9 (0.60 to 3093.81)	0.085	164	0.94±1.31 (0.06 to 15.04)	0.967
<b>SBP<sub>Slope</sub></b>	158	-1.34±1.06 (-3.44 to 0.75)	0.208	159	35.86±73.07 (0.64 to 2185.63)	0.079	159	2.01±2.32 (0.21 to 20.26)	0.544
<b>DBP<sub>Slope</sub></b>	158	-3.35±2.00 (-7.30 to 0.59)	0.094	159	33.15±120.63 (0.02 to 31305.88)	0.336	159	2.64±5.72 (0.04 to 199.22)	0.654
<b>HRE</b>	157	0.19±0.31 (-0.42 to 0.81)	0.526	158	0.94±0.53 (0.31 to 2.98)	0.908	158	0.99±0.33 (0.51 to 1.92)	0.975
<b>Pulmonary predictors</b>									
<b>RR<sub>Peak</sub> (same as F)</b>	159	0.02±0.02	0.218	160	0.98±0.03	0.516	160	0.97±0.02	0.153

		(-0.01 to 0.06)		(0.91 to 1.04)		(0.93 to 1.01)			
<b>VE<sub>Peak</sub> (VT * RR)</b>	<b>163</b>	<b>0.03±0.01</b> <b>(0.01 to 0.05)</b>	<b>0.011</b>	<b>166</b>	<b>0.95±0.02</b> <b>(0.91 to 0.99)</b>	<b>0.028</b>	<b>166</b>	<b>0.97±0.01</b> <b>(0.95 to 0.998)</b>	<b>0.040</b>
<b>VT<sub>Peak</sub> (tidal volume)</b>	160	0.60±0.50 (-0.40 to 1.60)	0.235	161	0.36±0.33 (0.05 to 2.00)	0.265	161	0.63±0.35 (0.21 to 1.86)	0.408
<b>VE/VCO<sub>2Peak</sub></b>	163	0.04±0.04 (-0.04 to 0.11)	0.371	166	1.02±0.06 (0.89 to 1.15)	0.704	166	1.01±0.04 (0.93 to 1.1)	0.762
<b>RV/TLC (baseline)</b>	<b>163</b>	<b>-0.08±0.04</b> <b>(-0.16 to -0.01)</b>	<b>0.035</b>	166	1.04±0.07 (0.91 to 1.19)	0.590	166	1.08±0.05 (0.99 to 1.17)	0.084
<b>FRC/TLC (baseline)</b>	157	-0.02±0.03 (-0.07 to 0.03)	0.487	158	1.06±0.05 (0.97 to 1.17)	0.229	158	1.05±0.03 (0.99 to 1.11)	0.127
<b>SHS Exposure predictors</b>									
<b>Airline SHS exposure (years)</b>	163	-0.02±0.02 (-0.05 to 0.02)	0.365	166	1.05±0.03 (0.99 to 1.11)	0.119	<b>166</b>	<b>1.04±0.02</b> <b>(1.005 to 1.08)</b>	<b>0.029</b>
<b>Childhood home SHS exposure (Y/N)</b>	<b>127</b>	<b>-0.72±0.35</b> <b>(-1.42 to -0.02)</b>	<b>0.043</b>	130	0.91±0.49 (0.32 to 2.72)	0.861	130	1.21±0.47 (0.57 to 2.58)	0.615
<b>Adult home SHS exposure (Y/N)</b>	127	-0.22±0.38 (-0.98 to 0.53)	0.556	130	0.9±0.5 (0.29 to 2.61)	0.845	130	2.18±0.93 (0.96 to 5.14)	0.066
<b>Non-airline occupational SHS exposure (Y/N)</b>	125	0.09±0.35 (-0.61 to 0.80)	0.794	128	0.55±0.33 (0.16 to 1.67)	0.313	128	1.1±0.43 (0.52 to 2.37)	0.795

Footnote: Associations of respiratory symptoms at rest (mMRC and FAMRI questionnaires) and during exercise (Borg) (outcomes) with each of the cardiopulmonary exercise outputs and SHS exposure (predictors) were assessed by univariate linear regression models with adjustment for age, sex, height, BMI, and corresponding baseline values (for slope predictors). Results for significant predictors are shown in bold. Abbreviations- VO<sub>2Peak</sub>: peak oxygen uptake; SHS: secondhand smoke, O<sub>2</sub>-Pulse<sub>Peak</sub>: oxygen uptake per heartbeat at peak exercise; HR: heart rate; SBP: systolic blood pressure; DBP: diastolic blood pressure; HRE: hypertensive response to

exercise based on at least meeting one criterion;  $RR_{Peak}$ : peak respiratory rate;  $VE_{Peak}$ : peak minute ventilation value;  $VT_{Peak}$ : peak tidal volume; RV: residual volume; TLC: total lung capacity; FRC: functional residual capacity.

**Table 7- Associations of cardiovascular response to exercise (outcomes) with years of exposure to cabin SHS (predictor).**

<b>Cardiovascular outcomes</b>	<b>N</b>	<b>Cabin SHS exposure Estimate±SEM</b>	<b>95% CI</b>	<b>P value</b>
<b>Peaks</b>				
<b>O<sub>2</sub>-Pulse<sub>Peak</sub></b>	<b>166</b>	<b>-0.0360±0.0177</b>	<b>-0.0710 to -0.0010</b>	<b>0.043</b>
HR <sub>Peak</sub>	166	0.0918±0.1495	-0.2034 to 0.3870	0.539
SBP <sub>Peak</sub>	159	-0.0635±0.1654	-0.3901 to 0.2632	0.702
DBP <sub>Peak</sub>	158	-0.1589±0.0855	-0.3279 to 0.0101	0.065
<b>Slopes</b>				
O <sub>2</sub> -Pulse <sub>Slope</sub>	164	-0.0001±0.0001	-0.0003 to 0.00001	0.139
HR <sub>Slope</sub>	164	0.0004±0.0011	-0.0017 to 0.0025	0.714
SBP <sub>Slope</sub>	159	-0.0012±0.0013	-0.0038 to 0.0014	0.349
DBP <sub>Slope</sub>	159	-0.0004±0.0007	-0.0018 to 0.0010	0.582
	<b>N</b>	<b>Odds ratio±SEM</b>	<b>95% CI</b>	<b>P value</b>
HRE	158	0.98±0.02	0.94 to 1.02	0.302

Footnote: Associations of each of the cardiovascular response to exercise (outcomes) with years of exposure to cabin SHS (predictor) were assessed by univariate linear regression models with adjustment for age, sex, height, BMI, and corresponding baseline values (for slope outcomes). Results for significant associations are shown in bold. Abbreviations- SHS: secondhand smoke, O<sub>2</sub>-Pulse: oxygen uptake per heartbeat; HR: heart rate; SBP: systolic blood pressure; DBP: diastolic blood pressure; HRE: hypertensive response to exercise based on meeting at least one criterion.

**Table 8- Mediation analysis of effect of SHS exposure on VO<sub>2Peak</sub> through cardiovascular outputs.**

<b>Mediator</b>	<b>N</b>	<b>Percent Mediated</b>	<b>2.5%</b>	<b>97.5%</b>	<b>P value</b>
<b>O<sub>2</sub>-Pulse<sub>Peak</sub></b>	<b>166</b>	<b>83.6</b>	<b>17.7</b>	<b>196.1</b>	<b>0.034</b>
HR <sub>Slope</sub>	166	9.0	-28.6	61.3	0.474
SBP <sub>Slope</sub>	159	-10.3	-110.8	84.1	0.580
DBP <sub>Slope</sub>	159	0.3	-116.0	100.2	0.936
RV/TLC	166	-3.7	-36.9	29.1	0.780
FRC/TLC	158	-7.6	-67.1	59.2	0.590

Footnote: To see if the association of SHS exposure with VO<sub>2Peak</sub> was mediated through the cardiovascular outputs, mediation analyses with bootstrapping were performed with adjustment for age, sex, height, and BMI and inclusion of one cardiovascular output at a time. Results from with and without bootstrap method are shown. Significant results are shown in bold.

Abbreviations- VO<sub>2Peak</sub>: peak oxygen uptake; SHS: secondhand smoke; O<sub>2</sub>-Pulse<sub>Peak</sub>: oxygen uptake per heartbeat at peak exercise; HR: heart rate; SBP: systolic blood pressure; DBP: diastolic blood pressure; RV: residual volume; TLC: total lung capacity; FRC: functional residual capacity.


**Table 9- Mediation analysis of effect of air trapping on  $VO_{2Peak}$  through cardiovascular outputs.**

<b>Mediation analysis of effect of FRC/TLC to <math>VO_{2Peak}</math></b>					
<b>Mediator</b>	<b>N</b>	<b>Percent Mediated</b>	<b>2.5%</b>	<b>97.5%</b>	<b>P value</b>
$O_2$ -Pulse <sub>Peak</sub>	158	59.9	-9.5	99.1	0.066
HR <sub>Slope</sub>	158	-3.3	-49.9	16.7	0.724
SBP <sub>Slope</sub>	154	4.0	-21.0	26.7	0.694
DBP <sub>Slope</sub>	154	21.4	-6.6	82.2	0.110
<b>Mediation analysis of effect of RV/TLC to <math>VO_{2Peak}</math></b>					
<b>Mediator</b>	<b>N</b>	<b>Percent Mediated</b>	<b>2.5%</b>	<b>97.5%</b>	<b>P value</b>
$O_2$ -Pulse <sub>Peak</sub>	166	51.8	-60.9	133.2	0.122
HR <sub>Slope</sub>	166	4.6	-33.2	39.6	0.576
SBP <sub>Slope</sub>	159	14.3	-4.4	67.5	0.096
DBP <sub>Slope</sub>	159	8.3	-40.3	55.7	0.538

Footnote: To see if the association of air trapping (FRC/TLC or RV/TLC) with  $VO_{2Peak}$  was mediated through the cardiovascular outputs, mediation analyses with bootstrapping were performed with adjustment for age, sex, height, and BMI and inclusion of one cardiovascular output at a time. Results from with and without bootstrap method are shown. Significant results are shown in bold. Abbreviations-  $VO_{2Peak}$ : peak oxygen uptake; RV: residual volume; TLC: total lung capacity; FRC: functional residual capacity;  $O_2$ -Pulse<sub>Peak</sub>: oxygen uptake per heartbeat at peak exercise; HR: heart rate; SBP: systolic blood pressure; DBP: diastolic blood pressure.

## FIGURES

Figure 1- Subject flow



**Figure 2- Proposed model referenced in the discussion.**

